Aspira is Transforming Women's Health

with Innovative Solutions

Aspira is led by an experienced team of business, medical and scientific professionals with a passion for improving health outcomes for women.

Meet our Leadership Team

About Aspira Women's Health

Our Mission

Aspira Women's Health is helping transform women’s health with the discovery, development, and utilization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. Our FDA-cleared products Ova1® and Overa® detect the risk of ovarian malignancy in women with adnexal masses. With over 10 years of experience in ovarian cancer risk assessment, Aspira Women's Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.

Learn More

Most Recent Press Releases

  • Aspira Women’s Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California

    Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid April 09, 2024 08:00 ET AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a new agreement with Anthem…

  • Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results

     March 28, 2024 07:30 ET  2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth quarter and full-year 2023 to $3.5 million and $15.9 million, respectively Conference Call and Webcast scheduled for today at 8:30 am…

  • View all Press Releases